Clinical trial
A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of…
NCT00042302 · QLT Inc., Industry · Terminated
Key facts
| NCT number | NCT00042302 |
|---|---|
| Title | A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Paclitaxel/Carboplatin as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC) |
| Lead sponsor | QLT Inc., Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Stage IIIb Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer |
| Intervention type | Drug, Procedure |
| Interventions | Chemotherapy, tariquidar + paclitaxel/carboplatin, placebo + paclitaxel/carboplatin |
| Enrollment | 540 |
| Start date | Jun 1, 2002 |
| Primary completion | Jul 1, 2003 |
| Completion | Jul 1, 2003 |
| First posted | Aug 1, 2002 |
| Last update posted | May 23, 2012 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: